Lithium

Lithium

SCHEMBL7180579

COc1ccc(PC(=O)c2c(C(F)(F)F)cccc2C(F)(F)F)c(OC)c1.[Li]

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
GAA P10253 2/20 0.44
LMNA P02545 1/20 0.44
ATM Q13315 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
MRGPRX4 Q96LA9 1/20 0.41
MAOB P27338 2/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
LPAR1 Q92633 1/20 0.39
TSHR P16473 1/20 0.38
CYP1A1 P04798 1/20 0.38
CYP1B1 Q16678 1/20 0.38
EPHX2 P34913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7180569 0.97 MAPT (0.44) MAPTNPSR1GAALMNAATM
SCHEMBL7180390 0.85 MAOB (0.40) MAPTNPSR1GAALMNAATM
Lithium SCHEMBL7177511 0.84 MAPT (0.52) MAPTGAASMN1; SMN2MEN1KMT2A
Lithium SCHEMBL7188957 0.83 RXRA (0.40) MAPTGAAMEN1KMT2AALDH1A1
Lithium SCHEMBL7182804 0.83 MAPK8 (0.33) MAPTNPSR1GAALMNAATM
SCHEMBL7179652 0.82 GAA (0.40) MAPTNPSR1GAALMNAATM
Lithium SCHEMBL7184703 0.82 KDM4E (0.42) MAPTLMNAKMT2AMRGPRX4MAOB
Lithium SCHEMBL7175318 0.82 ABCG2 (0.44) MAPTNPSR1LMNASMN1; SMN2MEN1
Lithium SCHEMBL7188548 0.82 KMT2A (0.45) MAPTGAALMNASMN1; SMN2MEN1
SCHEMBL7177504 0.81 MAPT (0.52) MAPTGAASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPT 4870/4885NPSR1 2669/4885GAA 4753/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAPT 4859/4885NPSR1 3007/4885GAA 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.